Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC or Lenvatinib Combined With Sintilimab as a Neoadjuvant Therapy for High Recurrence Risk Resectable Stage IB Solitary Hepatocellular Carcinoma
NCT05621499Active, not recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of sintilimab, lenvatinib, oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: 1-year Disease-Free Survival rate. Started Dec 2022; status: active, not recruiting.
02
Drugs
sintilimablenvatiniboxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05621499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621499.